# Comparison of CRP, Clinical Activity Indices and Fecal Lactoferrin with Disease Status in Ileocolonoscopy of Patients with IBD and IBS

**DDW 2006** Annual Scientific Meeting. May 20 - May 25, 2006. Los Angeles, CA

Jost Langhorst<sup>1</sup>, James Boone<sup>2</sup>, Andreas Rueffer<sup>3</sup>, Andreas Michalsen<sup>1</sup>, and Gustav Dobos<sup>1</sup> Department of Internal and Integrative Medicine V, Kliniken-Essen-Mitte, University of Duisburg-Essen, Germany, 2TECHLAB®, Inc., Blacksburg, Virginia USA and <sup>3</sup>Labor L+S/Enterosan, Bad Bocklet-Grossenbrach, Germany

### INTRODUCTION

Determining the presence of intestinal inflammation is the main criteria for the differentiation of irritable bowel syndrome (IBS) from inflammatory bowel disease (IBD) and for tailoring medical therapy. Clinical indices have proven too complex and time-consuming for daily routine practice leading to an assessment of clinical symptoms and use of independent lab parameters. Serological parameters for systemic inflammation such as C-reactive protein (CRP) and sedimentation rate are utilized often in the clinical assessment of IBD but are limited by low sensitivity and specificity for intestinal inflammation. Lactoferrin, a neutrophil-derived protein, has been shown to be a sensitive and specific indicator of intestinal inflammation in IBD. Recent studies have shown the correlation of elevated fecal lactoferrin (>7 ug/mL) to disease activity in IBD and the increase in levels as an indicator of relapse. Fecal lactoferrin is baseline in healthy subjects and in IBS. The aim of our study was to assess the correlation between levels of lactoferrin, serum CRP and disease activity indices to grades of intestinal inflammation as determined by endoscopic and histopathologic examinations of subjects suspected of IBD and

#### **METHODS**

Subject Population: A total of 63 adult patients, 22 Crohn's disease (CD), 21 ulcerative

colitis (UC) and 20 IBS were enrolled following informed consent at an adult IBD clinic over an 8 month period. A total of 35 patients was scored as active IBD by endoscopy. The mean age was 42 years and

the male:female ratio was 1:2.5.

Lab Parameters: Fecal lactoferrin was determined using ELISA (TECHLAB® IBD-SCAN®)

with a cut-off for elevated levels of >7 ug/mL. Serum CRP was

determined using an ELISA (CRPLX, Tina-quant, Roche/Hitachi) with a

positive cut-off of > 1 mg/dL.

A Colitis Activity Index (CAI) was used to assess subjects with UC using Activity Indices:

> a cut-off of > 5 calculated score for indicating active disease. The Crohn's Disease Activity index (CDAI) was calculated for CD and considered positive at > 150 calculated score. In the analysis for

correlation, the CAI and CDAI indices were combined.

Endoscopic Score: Endoscopically obtained histopathology specimens in addition to

macroscopic colonoscopy results were used as the standard reference. Each endoscopy was scored regarding inflammation: 0 for "no acute inflammation", 1 for "mild acute inflammation", 2 for "moderate acute inflammation" and 3 for "high acute inflammation". "No inflammation" was defined as the appearance of a healthy mucosa with no ulcerations. "Mild inflammation" was defined by erythema, decreased or absent vascular pattern, friability of mucosa and single aphthous lesions.

"Moderate inflammation" was defined as additional multiple aphthous lesions and small ulcers. "High inflammation" was characterized by additional presence of spontaneous bleeding, large ulcerous lesions,

nodules and/or narrowing.


Histopathology: Tissue biopsies were retrieved during the endoscopy exam from areas of disease involvement as determined visually. Slides were prepared

> using conventional hematoxylin-eosin (HE) stain and the magnification ranged from 50x to 400x. Each stain was graded as follows: "No inflammation" featured misshaped and asymmetric crypt architecture. "Mild inflammation" showed single crypt abscesses. "Moderate inflammation" was indicative of frequent crypt abscesses. "High

inflammation" was defined as increased infiltration of inflammatory cells


(neutrophils) into the lamina propria.

# **RESULTS** Figure 1. Correlation of Lactoferrin Levels to Endoscopy Score for Intestinal Inflammation



\*Statistical significance based on Student's T-test with P<0.05 Concentrations = mean±standard error

## Figure 2. Correlation of CRP Levels to Endoscopy Score for Intestinal Inflammation




\*Statistical significance based on Student's T-test with P<0.05 Concentrations = mean±standard error

### Table 1. Correlation Between Lactoferrin, CRP and Activity Index to Endoscopy

Parameter	Fecal Lactoferrin Level	Serum CRP Level	Activity Index (CAI/CDAI)
Correlation to Endoscopy	R= 0.73	R= 0.68	R = 0.58
Confidence intervals (95%)	0.59 to 0.80	0.52 to 0.79	0.19 to 0.67
Sensitivity	81%	51%	46%

### **RESULTS**

### Table 2. Endoscopic Pictures for CD and Histologic Slides for UC



#### CONCLUSIONS

·Lactoferrin levels showed the highest sensitivity and linear correlation (R2) to endoscopy score for grading intestinal inflammation in patients being assessed for IBD and IBS.

·A significant difference (p<0.05) was observed with lactoferrin between levels of mild and severe intestinal inflammation, and with no inflammation. CRP only showed a significant difference between severe and no intestinal

·Lactoferrin and serum CRP showed a similar overall correlation to endoscopy and histopathology results.

•The CDAI and CAI Indices showed a poor correlation to endoscopic and histologic results.

#### REFERENCES CITED

- 1. Kane, S., Sandborn, W., Rufo, P., Zholudev, A, Boone, J., Lyerly, D., Camilleri, M., and S. Hanauer. 2003. Fecal Lactoferrin is a Sensitive and Specific Marker in Identifying Intestinal Inflammation. Am. J. Gastroenterol. 98:1309-1314.
- 2. Parsi, M., Shen, B., Achkar, J., Remzi, F., Goldblum, J., Boone, J., Lin, D., Connor, J., Fazio, V., and B. Lashner. 2004. Fecal Lactoferrin for the Diagnosis of Symptomatic Patients with Ileal Pouch-anal Anastomosis. Gastroenterology, 126:1280-1286.
- 3. Buderus, S., Boone, J., Lyerly, D., and M. Lentze. 2003. Fecal Lactoferrin: New Parameter to Monitor Infliximab Therapy. Dig. Dis. And Sciences. 49:1036-1039.
- 4. Langhorst, J., Elsenbruch, S., Mueller, T., Rueffer, A., Spahn, G., Michalsen, A., and G. Dobos. 2005. A Comparison Among Four Neutrophil-derived Proteins in Feces as an Indicator of Disease Activity in Ulcerative Colitis. Inflamm. Bowel Dis. 11(12):1085-1091.

iost.langhorst@gmx.de / ihboone@techlab.com